Related Experiment Videos

High-dose melphalan is not associated with extramedullary relapses in high-risk multiple myeloma

P Moreau, R Bataille, B Mahé

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology

|September 1, 1993

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis.

Medecine et maladies infectieuses·2020

Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/-R) is an effective treatment with low toxicity in Hodgkin's and non-Hodgkin's lymphomas.

Annals of hematology·2017

Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis.

Cancer treatment reviews·2016

Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience.

Annals of hematology·2016

Improvement of overall survival after allogeneic hematopoietic stem cell transplantation for children and adolescents: a three-decade experience of a single institution.

Bone marrow transplantation·2015

Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study.

Annals of oncology : official journal of the European Society for Medical Oncology·2015

See all related articles